Table 2.

Demographic, clinical, and genotypic characteristics of validation cohort.

Variable	N=149
Females	47.3%
Males	52.7%
Age, (mean ± SD)	59.2 (16.3)
West African ancestry (mean ± SD)	76.3% (8%)
Weight, kg (mean ± SD)	96.5 (28.7)
Height, cm (mean ± SD)	170.5 (11.6)
Warfarin dose, mg/week (mean ± SD)	46.9 (17.2)
DVT/PE (%with)	59.70%
Atrial Fibrillation (%with)	16.1%
CYP2C9 inducers†	1.3%
Amiodarone	6.7%
SNP	MAF (allele)
CYP2C9 Star Variants	0.14*
CYP2C9 18786, rs7089580	0.19 (T)
VKORC1 (−1639), rs9923231	0.06 (A)
VKORC1 (−8191), rs61162043	0.47 (A)
rs12777823	0.26 (A)

SNP, single nucleotide polymorphism

MAF, minor allele frequency

^*Combined MAFs

^†Enzyme inducers considered were Carbamazapine, Rifampin, Statins, and Azole drugs